Ana Mafalda A. D. M. E. O.
- Country
- Spain
- Department
- Oncology
Research Overview
- Evaluation of Talimogene Laherparepvec and Atezolizumab Combination in Residual Breast Cancer Post-Neoadjuvant Chemotherapy in Pre and Post-Menopausal Women
- Phase 1 Evaluation of ATV-1601 in Patients with Advanced Solid Tumors and Breast Cancer Harboring AKT1 E17K Mutations
- A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of BG-75202 as Monotherapy and in Combination Therapy in Patients with Advanced Solid Tumors
Data & Insights
Has run more than one trial at 196 of 375 partner sites.
Specializations
Advanced Breast Oncology
The investigator concentrates on hormone‑driven malignancies, particularly Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer and related subtypes.
- HR+/HER2‑ metastatic disease
- CDK4/6 inhibitor resistance mechanisms
- BRCA‑mutated and HR‑deficient breast tumors
- Neoadjuvant endocrine therapy evaluation
Research efforts aim to improve outcomes for patients with refractory or relapsed disease through targeted molecular strategies.
Thoracic Malignancies
Work in the department includes extensive studies of Non‑Small Cell Lung Cancer, Small Cell Lung Cancer and molecularly defined subsets such as KRAS‑mutated disease.
- KRAS G12C‑positive NSCLC
- EGFR‑mutant resistant NSCLC
- Second‑line treatment for extensive‑stage SCLC
- Brain metastasis management in lung cancer
These programs focus on integrating novel targeted agents and immunotherapies into standard regimens.
Hematologic Malignancies
The investigator’s portfolio covers aggressive and indolent blood cancers, including Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma and various lymphomas.
- FLT3‑ITD and NPM1‑mutated AML
- BTK‑inhibitor based CLL therapy
- CAR‑T cell approaches for refractory B‑cell lymphoma
- Proteasome inhibitor combinations in myeloma
Clinical programs target resistance pathways and aim to extend durable remissions.
Gastro‑intestinal and Hepatobiliary Oncology
Key interests include solid tumors of the digestive tract such as Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer and Pancreatic Ductal Adenocarcinoma.
- Microsatellite instability‑high colorectal disease
- FGFR2‑positive cholangiocarcinoma
- HER2‑positive gastric carcinoma
- KRAS‑mutated pancreatic cancer
Efforts emphasize biomarker‑driven therapies and combination regimens to overcome treatment‑refractory disease.
Autoimmune and Inflammatory Disorders
Beyond oncology, the investigator engages in translational studies of immune‑mediated conditions such as Systemic Lupus Erythematosus, Myasthenia Gravis and Psoriatic Arthritis.
- Targeted B‑cell depletion in lupus nephritis
- Complement inhibition in refractory myasthenia gravis
- IL‑17 pathway blockade for psoriatic arthritis
- Biomarker profiling of disease activity
These programs seek novel immunomodulatory approaches to improve disease control and quality of life.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.